This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilson, R. H. Articles by Grem, J. L. Search for Related Content PubMed PubMed Citation Articles by Wilson, R. H. Articles by Grem, J. L. Social Bookmarking                            What's this?

Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability

From the Center for Cancer Research, National Cancer Institute, and Electromyography Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

Address reprint requests to Jean L. Grem, MD, NCI-Navy Oncology, National Naval Medical Center, Building 8, Room 5101, 8901 Wisconsin Ave, Bethesda, MD, 20889-5105; email: gremj{at}mail.nih.gov

PURPOSE: Oxaliplatin is a novel platinum compound with clinical activity in several malignancies. Neurotoxicity is dose-limiting and occurs in two distinct forms, an acute neurologic symptom complex that occurs within hours or days of therapy and a chronic, cumulative sensory neuropathy.

PATIENTS AND METHODS: Patients were treated in a phase I study designed to establish the maximum-tolerated dose of capecitabine given with oxaliplatin. Because of the unusual neurosensory toxicity of oxaliplatin, detailed neurologic examination, needle electromyography (EMG), and nerve conduction studies (NCS) were performed before and the day after oxaliplatin in a subset of 13 patients. Carbamazepine therapy was tried in 12 additional patients to determine whether the neurologic effects might be relieved.

RESULTS: All patients experienced acute, reversible neurotoxicities with oxaliplatin. Symptoms included paresthesias, dysesthesias, cold hypersensitivity, jaw pain, eye pain, pain in the arm used for drug infusion, ptosis, leg cramps, and visual and voice changes. Serial EMG and NCS revealed striking signs of hyperexcitability in motor nerves after oxaliplatin. In patients who achieved therapeutic levels, carbamazepine did not alter the clinical or electromyographic abnormalities.

CONCLUSION: The acute neurotoxicity seen with oxaliplatin is characterized by peripheral-nerve hyperexcitability, and the findings are similar to the clinical manifestations of neuromyotonia. Carbamezepine, which provides symptomatic relief in acquired neuromytonia, did not seem to be beneficial. Efforts to identify a successful neuroprotectant strategy would have a major impact on improving patient quality of life and the ability to deliver full doses of oxaliplatin.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. B. Park, C. S.-Y. Lin, A. V. Krishnan, D. Goldstein, M. L. Friedlander, and M. C. Kiernan Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy Brain, October 1, 2009; 132(10): 2712 - 2723. [Abstract] [Full Text] [PDF]

				A. Adenis, A. Mailliez, J.-M. Rigot, L. Gamelin, M. Vanhuyse, and E. Gamelin Recurrent Priapism Related to Oxaliplatin Infusion J. Clin. Oncol., February 20, 2008; 26(6): 1016 - 1017. [Full Text] [PDF]

				L. Gamelin, O. Capitain, A. Morel, A. Dumont, S. Traore, L. B. Anne, S. Gilles, M. Boisdron-Celle, and E. Gamelin Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway Clin. Cancer Res., November 1, 2007; 13(21): 6359 - 6368. [Abstract] [Full Text] [PDF]

				S. L. Spunt, B. B. Freeman III, C. A. Billups, V. McPherson, R. B. Khan, C. B. Pratt, and C. F. Stewart Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors J. Clin. Oncol., June 1, 2007; 25(16): 2274 - 2280. [Abstract] [Full Text] [PDF]

				R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad Orofacial Pain in Cancer: Part I--Mechanisms Journal of Dental Research, June 1, 2007; 86(6): 491 - 505. [Abstract] [Full Text] [PDF]

				S. R. Land, J. A. Kopec, R. S. Cecchini, P. A. Ganz, H. S. Wieand, L. H. Colangelo, K. Murphy, J. P. Kuebler, T. E. Seay, B. M. Needles, et al. Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07 J. Clin. Oncol., June 1, 2007; 25(16): 2205 - 2211. [Abstract] [Full Text] [PDF]

				W.-S. Wang, J.-K. Lin, T.-C. Lin, W.-S. Chen, J.-K. Jiang, H.-S. Wang, T.-J. Chiou, J.-H. Liu, C.-C. Yen, and P.-M. Chen Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients Oncologist, March 1, 2007; 12(3): 312 - 319. [Abstract] [Full Text] [PDF]

				T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M.-A. Loriot Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy. Clin. Cancer Res., May 15, 2006; 12(10): 3050 - 3056. [Abstract] [Full Text] [PDF]

				R. Mattioli, C. Massacesi, F. Recchia, F. Marcucci, C. Cappelletti, L. Imperatori, A. Pilone, M. Rocchi, A. Cesta, G. Laici, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer Ann. Onc., July 1, 2005; 16(7): 1147 - 1151. [Abstract] [Full Text] [PDF]

				R. J Cersosimo Oxaliplatin-Associated Neuropathy: A Review Ann. Pharmacother., January 1, 2005; 39(1): 128 - 135. [Abstract] [Full Text] [PDF]

				D. Santini, B. Vincenzi, A. La Cesa, M. Casale, F. Salvinelli, and G. Tonini Recurrent Episodes of Involuntary Masticatory Spasms Induced by Continuous Infusion of Oxaliplatin J Natl Cancer Inst, October 15, 2003; 95(20): 1555 - 1556. [Full Text] [PDF]

				S. Suresh, S. Lozono, and S. C. Hall Large-Dose Intravenous Methotrexate-Induced Cutaneous Toxicity: Can Oral Magnesium Oxide Reduce Pain? Anesth. Analg., May 1, 2003; 96(5): 1413 - 1414. [Abstract] [Full Text] [PDF]

				E. Winquist, M. Vincent, and W. Stadler Acute Bilateral Abducens Paralysis Due to Oxaliplatin J Natl Cancer Inst, March 19, 2003; 95(6): 488 - 489. [Full Text] [PDF]

				R. Schmelz, C. Lersch, J. L. Grem, T. Lehky, R. Thomas, M. Quinn, and M. K. Floeter Acute Oxaliplatin-Induced Peripheral-Nerve Hyperexcitability J. Clin. Oncol., August 15, 2002; 20(16): 3561 - 3562. [Full Text] [PDF]